Apogee Therapeutics (APGE) Return on Capital Employed (2023 - 2026)

Apogee Therapeutics (APGE) has 4 years of Return on Capital Employed data on file, last reported at 6.78% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 6.78%, up 223.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 6.78% (up 223.0% YoY), and the FY2025 annual result was 6.56%, up 40.0% from the prior year.
• Return on Capital Employed improved to 6.78% in Q1 2026 per APGE's latest filing, from 7.12% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 4.48% in Q4 2023 and troughed at 26.76% in Q3 2023.
• A 4-year average of 10.93% and a median of 8.68% in 2024 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2024 and 2025: Return on Capital Employed surged 1316 bps in 2024, then plunged 540 bps in 2025.
• A 4-year view of Return on Capital Employed shows it stood at 4.48% in 2023, then declined by 16 bps to 5.19% in 2024, then plunged by 37 bps to 7.12% in 2025, then increased by 5 bps to 6.78% in 2026.
• Business Quant data shows APGE's Return on Capital Employed at 6.78% in Q1 2026, 7.12% in Q4 2025, and 17.24% in Q3 2025.